T1	Participants 48 100	healthy subjects receiving sertraline and lorazepam.
T2	Participants 102 169	Patients suffering from some psychiatric and neurological disorders
T3	Participants 327 355	patients with schizophrenia.
T4	Participants 711 734	Twenty healthy subjects
